

May 21, 2019



Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019

BEDMINSTER, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- [Matinas BioPharma Holdings, Inc.](#) (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal ("LNC") formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, has been selected for two presentations at the ASM Microbe 2019 scientific meeting being held June 20–24 in San Francisco, CA.

The details for the ASM Microbe 2019 presentations are as follows:

Poster
Presentation

Session Title: AAR06 - Novel Approaches: Therapies, Diagnostics and Drug Discovery for Mycobacteria

Abstract Title: *"Oral Delivery of Amikacin-Lipid Nano-Crystal Formulations Safely and Effectively Treat Mycobacteria Infections in a Mouse Model of Cystic Fibrosis"*

Session Date: Friday, June 21, 2019

Presentation Time: 11:00 am – 12:00 pm PT and 4:00 pm – 5:00 pm PT

Presenter: Raphael Mannino, Ph.D.

Oral
Presentation

Poster Talk Title: Preclinical Leads for TB and NTM Infections

Presentation Title: *"Oral Delivery of Amikacin-Lipid Nano-Crystal Formulations Safely and Effectively Treat Mycobacteria Infections in a Mouse Model of Cystic Fibrosis"*

Session Date: Friday, June 21, 2019

Presentation Time: 1:15 pm – 2:15 pm PT
Presenter: Raphael Mannino, Ph.D.
Location: AAR Lounge and Learn, South, Level 2

About MAT2501

MAT2501, an orally administered, LNC formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, which is currently available to patients only in IV formulations. Amikacin is currently used to treat different types of chronic and acute bacterial infections, including non-tuberculous mycobacterium (NTM) infections and various multi-drug resistant gram negative bacterial infections. IV-administered amikacin is associated with major side effects including nephrotoxicity and ototoxicity (permanent loss of hearing).

MAT2501 is designed to provide targeted delivery of the potent antibiotic amikacin while providing a significantly improved safety and tolerability profile. In preclinical studies MAT2501 demonstrated efficacy after oral bioavailability in murine models of both pulmonary (lung) and disseminated NTM infections. The FDA designated MAT2501 as a QIDP and an Orphan Drug for the treatment of NTM infections.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal ("LNC") platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

For more information, please visit www.matinasbiopharma.com and connect with the Company on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Matinas Forward-Looking Statements: *This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company's ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval*

and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates, including MAT2203 and MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP), Orphan and/or Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

Investor Contact Matinas Biopharma

Jenene Thomas

Jenene Thomas Communications, LLC

Phone: +1 (833) 475-8247

Email: mtnb@jtcir.com

Source: Matinas BioPharma Holdings, Inc.



Source: Matinas BioPharma Holdings, Inc.